Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. of Beijing at MEDICA 2018 in Düsseldorf -- MEDICA - World Forum for Medicine
Manufacturers

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

No. 31 Kexueyuan Road, Changping District, 102206 Beijing
China
Telephone +86 10 59528888
Fax +86 10 59528999
wtexport@ystwt.com

Hall map

MEDICA 2018 hall map (Hall 3): stand K23

Fairground map

MEDICA 2018 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostics
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.01  Immuno assay testing

Immuno assay testing

Our products

Product category: Immuno assay testing

Hepatitis E

Every year an estimated 20 million HEV infections occur worldwide, leading to more than three million symptomatic cases of Hepatitis E. The virus can be detected using Beijing Wantai’s diagnostic products.

The Hepatitis E virus (HEV) is a non-enveloped, single stranded RNA virus primarily transmitted through the fecal-oral route, blood transfusion and possibly maternal-fetal. Infection with HEV causes acute sporadic and epidemic viral Hepatitis and induces acute or subclinical liver diseases similar to Hepatitis A. While there are four major genotypes of HEV, there is only one serotype.

Every year an estimated 20 million HEV infections occur worldwide, leading to more than three million symptomatic cases of Hepatitis E. The World Health Organization estimates that Hepatitis E caused approximately 44 000 deaths in 2015.

While endemic and frequently epidemic HEV infections occur mainly in developing countries with limited or no access to essential water, sanitation, hygiene and health services, the virus has also been observed in developed countries with or without a history of traveling to endemic areas. Data published throughout the last ten years has shown that locally-acquired Hepatitis E in Europe and other developed countries is also common. Persistent HEV infections can occur especially in immune-suppressed cases, e.g. organ transplant recipients or people infected with HIV.

Transmission through the fecal-oral route is common in countries with limited or no access to essential water, sanitation, hygiene and health services. Water and food supplies that are contaminated can lead to major outbreaks. Sporadic cases in countries with better sanitation are often caused by infection through ingestion of undercooked animal meat including animal liver.

HEV transmission by blood transfusion is another route of infection. A study conducted between 2002 and 2008 in China, with 44,816 donor samples, found HEV seroprevalences in blood donors ranged from 29.9% to 41.7%. The rate of acute HEV infection was 0.43% to 1.51%. The viremia rates among the donors in six different regions of China ranged from 0.02% to 0.14%. The results also showed a high prevalence of viremia among anti-HEV IgM-positive samples. A total of 7.14% (30/420) of anti-HEV IgM-positive samples were RNA positive but none of the IgM-negative samples were HEV RNA positive.

Recent seroprevalence studies indicate high prevalence of HEV infection among healthy populations in some industrial countries with historically low occurrence of Hepatitis E including the US, Japan and Europe.

Symptomatic HEV infection is most common in adults aged 15-40 years. Mortality rates for severe forms of Hepatitis E range between 0.5% - 4.0% of the overall population. During pregnancy in the 3rd trimester this severe form of Hepatitis may reach a mortality rate of 20%.

In patients infected with HEV, IgM antibodies typically appear first, followed by IgG seroconversion. The level of IgM antibodies declines rapidly in the acute phase of the infection; the IgG antibodies are present for up to 14 years.

Hepatitis E can be detected using Beijing Wantai’s diagnostic products. Our ELISA kits are intended for use in clinical laboratories for diagnosis and management of the Hepatitis E virus infections while our rapid test delivers a quick result in only 10 minutes. RNA detection with PCR can also be used for diagnosis of HEV infection. Our anti-HEV antigen (Ag)–specific ELISA offers an inexpensive alternative to PCR.

In 2012 the world’s first Hepatitis E vaccine Hecolin® was developed by our subsidiary Innovax [link to Innovax About]. The product Find out more about Hecolin®

More Less

Product category: Immuno assay testing

HIV

The human immunodeficiency virus, HIV, continues to be a major global health issue with millions of people around the world living with HIV. Every year large numbers of people are being newly infected. Beijing Wantai is leading innovations in HIV testing.

The human immunodeficiency virus, commonly referred to as HIV, attacks and deteriorates the body’s immune system, which can lead to immune deficiency. Apart from sexual transmission, the principal route of infection with the virus is blood transfusion. If not treated, infection with the virus can lead to acquired immunodeficiency syndrome (AIDS), the third stage of HIV infection – the first two being acute HIV infection and clinical latency (also referred to as asymptomatic HIV).

According to statistics released by the World Health Organization, 36.7 million people globally were living with HIV at the end of 2016; 1.8 million people were newly infected in 2016.

Serological evidence of infection can be obtained by testing for presence of HIV antibodies and antigens. While antibodies can be detected throughout all phases of infection, antigens can only be detected during the acute phase and the symptomatic phase of AIDS.
During the acute phase and the symptomatic phase of AIDS, serological evidence of infection can be obtained by testing for presence of HIV antigens.

Due to the possibility of transmission through contaminated blood as well as the fact that HIV can be present in both cellular and cell free fractions of human blood, all blood and plasma donations should be tested against HIV. Beijing Wantai is leading innovations in HIV testing.

More Less

Product category: Immuno assay testing

Tuberculosis

Tuberculosis continuous to be one of the top 10 causes of death globally. The infectious disease which is spread from person to person through the air can be detected using Beijing Wantai’s diagnostic products.

Tuberculosis (TB) is an infectious disease caused by various strains of mycobacteria, usually Mycobacterium Tuberculosis, which is spread from person to person through the air when an infected person coughs sneezes or otherwise transmits saliva through the air. While the disease typically attacks the lungs, it can also affect other parts of the body.

According to World Health Organization estimates, 10.4 million people were infected with Tuberculosis in 2016 and 1.7 million died from the disease. It is one of the world’s top 10 causes of death.

Approximately one tenth of latent or asymptomatic infections eventually progress to active TB, which, if left untreated, kills more than 50% of those infected individuals. Tuberculosis has been observed worldwide; however, most deaths occur in low- and middle-income countries.

Beijing Wantai’s TB-IGRA test aids in diagnosis of TB infection including both latent Tuberculosis infection and Tuberculosis disease.

More Less

About us

Company details

Beijing Wantai Biological Pharmacy is one of the leading manufacturers of infectious disease diagnostics and a global leader in Hepatitis E diagnostics.
Founded in 1991, Beijing Wantai has grown from a small laboratory to one of the biggest and most influential Chinese manufacturers of in vitro diagnostic tests and is leading the way in blood transfusion and infectious immunology.

As Asia-Pacific’s largest HIV diagnostic reagent production base we have dominated the reagent market for the past 15 years; our Hepatitis C and Syphilis detection reagents have been top products in the market for several years.

At Beijing Wantai we are specialised in manufacturing ELISA kits and rapid tests for infectious disease diagnostics, producing and distributing medical chemical reagents, and researching – as well as manufacturing – quality control materials.

We service both international and domestic customers including blood banks, hospitals and clinics, reference laboratories, border inspection centres, blood-processing companies, and research institutes.

Our headquarters are located in the biotechnology heart of Beijing at Zhongguancun Life Science Park Beijing. We specialise in the production of diagnostic tests, quality control materials, diagnostic instruments, research and development of new materials, and vaccines.

Our Beijing plant is the largest manufacturing base for the production of immunodiagnostic reagents in China. Our state-of-the-art production facilities are GMP, ISO9001 and ISO13485 certified and our products undergo strict quality and cost controls. Most of our products bear the CE marking including our HCV, HBsAg and HIV ELISA kits. Our HIV Rapid test and HIV ELISA kit are WHO pre-qualified ensuring that that test kits can be used globally where they are needed.

Beijing Wantai is the biopharma arm of Yangshengtang Group and employs more than 1000 people. In 2016, we were selected to participate in the Ministry of Science and 12th national Science & Technology Achievements Exhibition.

More Less